Literature DB >> 6881022

Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion.

P E Fenster, K A Comess, R Marsh, C Katzenberg, W D Hager.   

Abstract

We evaluated the efficacy of an intravenous infusion of procainamide in 26 consecutive candidates for cardioversion of atrial fibrillation. Procainamide was administered at a rate of 15 to 20 mg/min up to a maximum of 1000 mg. The treatment was considered effective only if cardioversion occurred during the procainamide infusion. Conversion to sinus rhythm occurred in 15 patients. Converters had a significantly shorter mean duration of atrial fibrillation (6 +/- 7 days, mean +/- S.D.) compared to nonconverters (79 +/- 88 days) (p less than 0.01). The mean left atrial size of converters (4.3 +/- 0.6 cm) did not differ significantly from that of nonconverters (4.7 +/- 0.9 cm). The dose of procainamide required for cardioversion ranged from 3.6 to 16.4 mg/kg. Two patients developed nonsustained ventricular tachycardia, and there was one episode of bifascicular block during the infusion. Intravenous procainamide is an effective form of therapy for conversion of atrial fibrillation of new onset.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6881022     DOI: 10.1016/0002-8703(83)90692-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

Review 1.  In-hospital approach to newly recognized atrial fibrillation.

Authors:  C D Kimmelstiel; M Homoud; C A Clyne; M Estes III
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Pilsicainide for atrial fibrillation.

Authors:  Koichiro Kumagai; Hideko Nakashima; Hideaki Tojo; Tomoo Yasuda; Hiroo Noguchi; Naomichi Matsumoto; Masahiro Ogawa; Keijiro Saku
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Cardioversion with flecainide in patients with atrial fibrillation of recent onset.

Authors:  J J Goy; R Maendly; M Grbic; L Finci; U Sigwart
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk.

Authors:  I Schnittger
Journal:  Br Heart J       Date:  1995-04

Review 5.  [Pharmacological cardioversion of atrial fibrillation].

Authors:  J R Ehrlich; S H Hohnloser
Journal:  Z Kardiol       Date:  2005-01

Review 6.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

7.  Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study.

Authors:  F Bellandi; R P Dabizzi; F Cantini; M D Natale; L Niccoli
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

8.  Conversion of paroxysmal atrial fibrillation to sinus rhythm by intravenous pirmenol. A placebo controlled study.

Authors:  L K Toivonen; M S Nieminen; V Manninen; M H Frick
Journal:  Br Heart J       Date:  1986-02

Review 9.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

10.  Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone.

Authors:  M J Chapman; J L Moran; M S O'Fathartaigh; A R Peisach; D N Cunningham
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.